D-dimer Testing Market Size To Reach $2.7 Billion By 2033

October 2026 | Report Format: Electronic (PDF)

D-dimer Testing Market Growth & Trends

The global D-dimer testing market size is expected to reach USD 2.7 billion in 2033, a registering a CAGR of 3.7% from 2026 to 2033, according to a new report by Grand View Research, Inc. Technological advancements in D-dimer testing have resulted in the development of a wide range of products that have allowed healthcare professionals to offer suitable emergency assistance to patients. The concept of automation in D-dimer testing has provided rapid, less labor-intensive, and user-friendly diagnostic strategies, which is expected to drive the market in the near future.

The commercially available assays often have differences in their antibody specificity as D-dimer antibodies also detect Fibrin Degradation Products (FDPs), leading to incorrect results. To address this issue, Advanced ImmunoChemical, Inc. has developed two monoclonal antibodies, which are used to design one-step immunoassay specific for both FDP and D-dimer. Thus, the development of improved immunoassays that equally detect all FDPs is expected to boost the market growth.

Extensive research for the determination of new D-dimer threshold values for a specific population set prevents the usage of Computed Tomography Pulmonary Angiography (CTPA). This is beneficial as the elimination of CTPA leads to low radiation exposure, which, in turn, increases the demand for the test. To demonstrate this, a group of researchers from Japan determined new elevated D-dimer threshold values for the diagnosis of pulmonary embolism in the Japanese population. Such studies are expected to favor market growth.

Request a free sample copy or view report summary: D-dimer Testing Market Report

D-dimer Testing Market Report Highlights

The reagents & consumables segment accounted for the largest share of 65.0% in the D-dimer testing market in 2025. Its strong position is driven by recurring purchases of assay reagents, kits, antibodies, calibrators, controls, cartridges, cuvettes, and other test-specific materials.
The clinical laboratory tests segment dominated the global market, accounting for 61.9% of revenue in 2025, led by high-volume testing across hospital laboratories, diagnostic centers, and reference laboratories.
The Enzyme-linked Immunosorbent Assay (ELISA) segment dominated the D-dimer testing market, accounting for 41.5% of revenue in 2025, fueled by its high analytical sensitivity, specificity, and quantitative capability.
The Deep Vein Thrombosis (DVT) segment dominated the market, accounting for 37.2% of revenue in 2025, supported by frequent evaluation of patients presenting with lower-extremity pain or swelling.
The hospitals segment accounted for the largest share of 36.8% in 2025, supported by high emergency, inpatient, outpatient, and laboratory testing volumes.
North America dominated the global D-dimer testing market, accounting for the largest revenue share of 33.8% in 2025, supported by advanced healthcare infrastructure, established laboratory networks, favorable reimbursement, and widespread coagulation testing.